Back to News
Market Impact: 0.3
What Amarin (AMRN) Said on Its Q3 Earnings Call
Source: marketbeat.com
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Amarin reported its first profitable quarter in two years in Q3 2026, supported by lower operating expenses, positive operating cash flow and growth in international in-market demand. Those gains helped offset continued U.S. pricing pressure for its VASCEPA cardiovascular therapy.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
AMRN0.60
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong
- Microsoft's Big Bets on AI Start to Pay Off
- Asian shares fall as Alphabet earnings miss drags Wall St futures lower